DarioHealth (NASDAQ:DRIO) posted its quarterly earnings results on Tuesday. The company reported ($7.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.02) by ($6.70), Fidelity Earnings reports. DarioHealth had a negative net margin of 234.63% and a negative return on equity of 216.56%.
DRIO stock opened at $3.50 on Friday. The company has a quick ratio of 1.35, a current ratio of 4.39 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $7.85 and a two-hundred day moving average price of $4.41. The company has a market cap of $8.50 million, a price-to-earnings ratio of -0.39 and a beta of 0.21. DarioHealth has a twelve month low of $3.02 and a twelve month high of $18.60.
DRIO has been the subject of a number of analyst reports. Craig Hallum decreased their price target on DarioHealth from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday. ValuEngine downgraded DarioHealth from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 6th.
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.
Featured Article: What are the components of an earnings report?
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.